TeleBasel Switzerland TV Interviews CordenPharma CEO Dr. Michael Quirmbach on 5 March 2025 – see Minute :40 for the section “Company invests half a Billion in Muttenz Switzerland”
It is a glimmer of hope for the financially stricken canton Basel-Landschaft. The Basel-based company CordenPharma is investing half a billion francs in its Muttenz site.
The group produces peptides that are also used in weight-loss drugs. The coffers of Canton Basel-Land will benefit considerably from this investment.
500 million francs for a new production building. For CordenPharma, as an international company, this is the largest investment in the Basel area and history. In the future, around 300 employees will be able to work at the Muttenz site.
“Yes, we decided on Muttenz partly because of its proximity to Basel, where we can easily find highly qualified employees, but also because we have a great infrastructure here at the Schweizerhalle site. Ultimately, it’s about chemical production, where this is an absolutely key criteria,” says CEO Dr. Michael Quirmbach.
CordenPharma already produces active ingredients for medications in Liestal, Ettingen and Fribourg. With the boom in weight-loss injections, demand for peptides has also risen sharply. With the 4th location in Muttenz, no great risk would be taken, says CEO Dr. Michael Quirmbach:
“We have concluded corresponding production contracts with companies, so the risk is not that great now. Of course, there is always a residual risk as a supplier, since companies can also drop out, but we are of course very confident that we can win other companies as customers too”.
The region is also pleased about the half-billion-franc investment.
“This is an investment decision that is rarely made. We can benefit from it in the first place because it revitalizes the entire life science cluster, strengthens production expertise, and benefits supplier companies – this is truly an excellent decision from the point of view of the Canton Basel-Landschaft,” says Thomas Kübler, Head of Location Promotion Basel-Landschaft.
The new site will also generate additional tax revenue for the Canton of Basel-Landschaft. With the budget in the red, investments like this are a blessing for the region. CordenPharma plans to start operations at the Muttenz site in 2028.
Watch “CordenPharma invests half a Billion in Muttenz Switzerland” online
Get in touch with our team of experts to explore bespoke end-to-end CDMO support of your complete drug lifecycle
at any scale.